SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richaaard who wrote (1013)3/30/1999 8:43:00 AM
From: Solomon  Read Replies (1) of 1837
 
Let's go over why a doctor would switch to Cenestin. - In today's prescription marketplace you have HMO's, PPO's, Case Managers, Drug Utilization Review, Formularies, ect. all getting between the Triad of physician-patient-pharmacist. If a drug like Cenestin get's on a large HMO's formulary because it's lower in cost (and it doesn't take much lower cost to get on some- just lower) the drug will sell, the physicians will write for it and the patient will take it. I get to see this interaction every day. A physician prescribes a non-formulary drug, the patient asks why it's not covered, I get to explain "it's not on your insurance co's formulary", the patient often asks me to phone the physician "for something that's covered". There are a few patients that pay for the prescription out of pocket. Most want to only pay their copay.
So- in todays marketplace- Cenestin should sell.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News